http://www.rigel.com/indexflash.php
http://finance.yahoo.com/q/ks?s=RIGL
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of small-molecule product candidates for the treatment of inflammatory diseases, cancer, and viral diseases in the United States. Its products include R112, a Phase II clinical trial completed product, which would be used for the treatment of allergic rhinitis; R788, Phase II clinical trial product, for the treatment of rheumatoid arthritis and thrombocytopenia; and R763, a Phase I clinical trial product, for the treatment of oncology. The company has collaborations agreements with Janssen Pharmaceutica N.V., Pfizer, Inc., Novartis Pharma AG, Daiichi Pharmaceuticals Co., Ltd., Merck and Co., Inc., and Serono. Rigel was incorporated in 1996 and is based in South San Francisco, California.

